The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | New and emerging drug targets for older AML patients
Nigel Russell, MD, of Guy’s Hospital NHS Trust, London, UK, explores new and emerging drug targets for acute myeloid leukemia (AML). Specifically discussed by Dr Russell is the use of venetoclax with azacitidine, updates in the VIALE-A study (NCT02993523) and magrolimab, an anti-CD47 antibody. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
